2016
Pacific Edge Launches Cxbladder Resolve - The Fourth Product in Suite of Cxbladder Tests
Cxbladder Resolve, a front line tool for urologists targeting the identification of patients with high grade and late stage disease, is now available to New Zealand urologists and will be progressively launched into other markets, including the USA, throughout 2017. [read more]
Pacific Edge Commences Official Launch of Cxbladder Monitor in the USA
Cxbladder Monitor is Pacific Edge’s third test in its Cxbladder suite of simple, accurate and non-invasive bladder cancer diagnostic tests and has been designed to be used on patients as part of their ongoing surveillance regime to quickly and accurately identify those who have a low probability of having recurrent cancers. [read more]
Cxbladder Monitor Paper to be Published in Prestigious Journal of Urology
The prestigious American Journal of Urology has accepted for publication a paper confirming the superior performance of Pacific Edge’s Cxbladder Monitor test for the surveillance of bladder cancer recurrence, offering patients with bladder cancer the potential utility of avoiding or deferring some cystoscopies. [read more]
Pacific Edge Interim Results to 30 September 2016
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has announced a solid first half result for the six months to 30 September 2016 as it continues to ramp up activity in the USA, with a number of significant commercial achievements in the six month period. [read more]
Positive Results in Kaiser Permanente User Programme
Cancer diagnostics company Pacific Edge (NZX: PEB) has advised that it has successfully completed its analysis of the data from the large scale Kaiser Permanente (Kaiser) User Programme with positive and compelling findings. [read more]
Half Year Financial Results to be Released on 24 November 2016
Pacific Edge Limited (NZX:PEB) intends to announce its half year results for the period ended 30 September 2016 (HY17) on Thursday 24 November 2016, prior to 10am NZDT. [read more]
Pacific Edge Announces User Programme with Singapore General Hospital
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has signed an agreement with Singapore General Hospital (SGH), the country’s first and largest hospital to conduct a User Programme (observational study) with Pacific Edge’s Cxbladder Triage and Cxbladder Detect tests. [read more]
Cxbladder Monitor Adopted by Waitemata District Health Board
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has received approval for its latest Cxbladder diagnostic technology, Cxbladder Monitor, from Waitemata District Health Board (WDHB) through the national procurement services of healthAlliance. [read more]
Pacific Edge Named in TIN100 Top 10 List
The growing success of cancer diagnostics company, Pacific Edge, has once again been recognised with company named in the 2016 TIN100 Top Ten list of Hot Emerging Companies for the second year in a row. [read more]
Pacific Edge Confirmed as Approved Provider to Tricare Network in US
The US subsidiary of cancer diagnostics company, Pacific Edge Limited (NZX:PEB), is now an approved provider as part of the TRICARE Health Plan network. [read more]
Pacific Edge and Cxbladder in USA Today
This past weekend in the US, Pacific Edge and Cxbladder featured in a publication titled "The Fight Against Cancer", which was included in over 450,000 issues of the USA Today in selected states, reaching some 1.3 million readers. [read more]
Private Insurance Coverage Confirmed for Cxbladder
Cancer diagnostics company, Pacific Edge (NZX:PEB) has advised that its Cxbladder diagnostics tests have been approved for reimbursement by a second major health insurance provider, nib Health Insurance in New Zealand. [read more]
Chris Gallaher Elected as New Chairman for Pacific Edge Board
The Board of cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has announced the election of Mr Chris Gallaher as Chairman, replacing Mr Chris Swann who, as previously advised, is stepping down from the Board at today’s Annual Shareholders’ Meeting. [read more]
Pacific Edge Annual Meeting 2016
The Pacific Edge annual meeting was held today in Dunedin, with shareholders voting in favour of all resolutions. [read more]
Pacific Edge 2016 Annual Meeting to Take Place on 25 August
Pacific Edge is holding its Annual Shareholders' Meeting on 25 August at the Dunedin Public Art Gallery. [read more]
PEB: Annual Report 2016
Pacific Edge is pleased to present its Annual Report for the year ended 31 March 2016. [read more]
Pacific Edge Wins MTANZ Innovation Award for Cxbladder Technology
Pacific Edge has won the Medical Technology Association of New Zealand (MTANZ) Innovation Award for its Cxbladder technology. [read more]
Pacific Edge Board Changes Announced
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has today announced some changes to its Board, including the appointment of Chris Gallaher as an Independent Director, effective from 1st July 2016. [read more]
PEB: Full Year Results to 31 March 2016
Pacific Edge Reports Another Year of Commercial Progress and Growth [read more]
Pacific Edge Presents Positive Cxbladder Monitor Results
Results Outperform Currently Available Tests for Monitoring Recurrent Urothelial Carcinoma Abstract Selected for Plenary Session at AUA 2016 [read more]
Request for Director Nominations
The date of the Pacific Edge Limited's Annual Meeting has been set for Thursday 25th August 2016. The meeting will be held in Dunedin. [read more]
Pacific Edge Collaborates On Launch Of Patient Community Site
Pacific Edge is proud to announce the official launch of bladdercancer.me, an online bladder cancer patient community which provides support, tools and information for patients, their families and care-givers. [read more]
Investor Update For April 2016
Pacific Edge Limited (NZX:PEB) has today released its April 2016 Investor Update newsletter. [read more]
Confirmation Of Director Appointment
Pacific Edge Limited (PEB:NZX) has today advised that David Levison’s appointment as a Director has been confirmed, effective as at 2 April 2016. [read more]
Pacific Edge Enters Commercial Agreement With Canterbury District Health Board
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has entered into a commercial agreement to provide its innovative Cxbladder diagnostic technology to the Canterbury District Health Board (CDHB) for primary care referral in the evaluation of haematuria [read more]
Pacific Edge Gain Access To Veterans Administration In USA
The USA subsidiary of global cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has signed a Federal Supply Schedule (FSS) agreement with Veterans Administration, which will allow the company to market its innovative, non-invasive bladder cancer detection technology, Cxbladder, to the Veterans Administration (VA), the nation's largest integrated health care system. [read more]
Pacific Edge Announces New Commercial Partnership In Australia
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has announced a new commercial partnership with Tolmar Australia Pty Limited, a specialised uro-oncology company which provides medicine and support to men with advanced prostate cancer. [read more]
PEB Advices New Director Appointment and Special Meeting
Cancer diagnostic company, Pacific Edge Limited (NZX: PEB) advises that US-based Director, David Levison, has accepted an invitation to join the Pacific Edge Limited Board of Directors. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.